Cantel Medical Announces Launch Of Three New Endoscope Reprocessors For Europe And Asia Pacific

- MEDIVATORS® ADVANTAGE PLUS® Pass-Thru Endoscope Reprocessor

- MEDIVATORS® ISA™ Endoscope Reprocessor

- MEDIVATORS® RAPIDAER® Endoscope Reprocessor

Nov 12, 2015, 16:20 ET from Cantel Medical Corp.

LITTLE FALLS, N.J., Nov. 12, 2015 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN) announced that it has recently launched three automated endoscope reprocessors for the European and Asia Pacific markets.  The introduction of these new endoscope reprocessors represents an important milestone in Cantel's expansion strategy outside of the United States.

Cantel introduced the MEDIVATORS ADVANTAGE PLUS Pass-Thru Automated Endoscope Reprocessor after receiving a CE mark in November 2015.  The design of this equipment is based on the highly successful MEDIVATORS ADVANTAGE PLUS platform but has been enhanced with additional features including ergonomic design, an intuitive operating system, faster cycle time and pass-through capability.  This system is manufactured in Cantel Medical's Plymouth, Minnesota facility and is being marketed and sold in European and Asia Pacific markets.

Cantel has also recently introduced the MEDIVATORS ISA Endoscope Reprocessor in Europe and Asia Pacific.  This product, manufactured by Cantel Medical in Italy, represents a fast, flexible and easy to use console endoscope reprocessor. Its intuitive operating system, fast cycle time and compact dimensions are designed to provide increased productivity for customers and an effective solution for endoscopy suites of all sizes.

The MEDIVATORS RAPIDAER Endoscope Reprocessor, initially introduced to the UK market in late 2014, has been upgraded and introduced to the broader European market in May 2015.  Manufactured by Cantel Medical in the United Kingdom, the MEDIVATORS RAPIDAER Endoscope Reprocessor was designed with reliability and productivity in mind. This system offers a flexible solution to suit all sizes of endoscopy departments and uses the latest modular construction methods to produce the fastest and smallest pass-through washer disinfector currently on the market.

"The MEDIVATORS ADVANTAGE PLUS Pass-Thru, MEDIVATORS ISA and MEDIVATORS RAPIDAER endoscope reprocessors represent our growing full circle Endoscopy portfolio and further evidence our commitment to delivering innovative, infection prevention products and solutions that meet the market specific needs of our global customers," said Dave Hemink, President of Medivators.  

"The design, production and launch of new endoscope reprocessors from our operations in the United Kingdom and Italy demonstrate the strategic value of our recent acquisitions in Europe and our ability to leverage our core capabilities and know-how," said Jorgen Hansen, President and Chief Operating Officer of Cantel Medical. "Our technology centers in the United Kingdom and in Italy provide new growth platforms with a broad range of capabilities in key markets throughout the world."

About Cantel Medical Corp.

Cantel Medical is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives.  Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products. Additionally, we provide technical service for our products. 

For further information, visit the Cantel website at www.cantelmedical.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.

 

SOURCE Cantel Medical Corp.



RELATED LINKS

http://www.cantelmedical.com